ascendis
pharma
announces
participation
annual
morgan
stanley
virtual
global
healthcare
conference
copenhagen
denmark
globe
newswire
ascendis
pharma
nasdaq
asnd
biopharmaceutical
company
utilizes
innovative
technologies
address
unmet
medical
needs
today
announced
company
participate
annual
morgan
stanley
virtual
global
healthcare
conference
september
company
executives
provide
business
overview
update
company
pipeline
programs
details
event
annual
morgan
stanley
virtual
global
healthcare
conference
location
virtual
date
thursday
september
time
eastern
time
live
webcast
presentation
available
investors
news
section
ascendis
pharma
website
webcast
replay
also
available
website
shortly
conclusion
events
days
ascendis
pharma
ascendis
pharma
applying
innovative
platform
technology
build
leading
fully
integrated
biopharma
company
focused
making
meaningful
difference
patients
lives
guided
core
values
patients
science
passion
company
utilizes
technologies
create
new
potentially
therapies
ascendis
pharma
currently
pipeline
three
independent
endocrinology
rare
disease
product
candidates
clinical
development
advancing
oncology
second
therapeutic
area
focus
company
continues
expand
additional
therapeutic
areas
address
unmet
patient
needs
ascendis
headquartered
copenhagen
denmark
additional
offices
heidelberg
berlin
germany
palo
alto
redwood
city
california
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
statements
historical
facts
included
press
release
regarding
ascendis
future
operations
plans
objectives
management
statements
examples
statements
include
limited
statements
relating
ascendis
ability
apply
platform
technology
build
leading
fully
integrated
biopharma
company
ii
ascendis
product
pipeline
expansion
additional
therapeutic
areas
iii
ascendis
expectations
regarding
ability
utilize
transcon
technologies
create
new
potentially
therapies
ascendis
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
statements
ascendis
makes
including
following
unforeseen
safety
efficacy
results
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
unforeseen
expenses
related
development
potential
commercialization
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
selling
general
administrative
expenses
research
development
expenses
ascendis
business
generally
delays
development
oncology
programs
transcon
hgh
transcon
pth
transcon
cnp
development
programs
related
manufacturing
regulatory
requirements
speed
patient
recruitment
unforeseen
delays
dependence
third
party
manufacturers
supply
study
drug
planned
clinical
studies
ascendis
ability
obtain
additional
funding
needed
support
business
activities
effects
business
worldwide
pandemic
description
risks
uncertainties
could
cause
actual
results
differ
expressed
statements
well
risks
relating
ascendis
business
general
see
ascendis
prospectus
supplement
filed
july
ascendis
current
future
reports
filed
submitted
securities
exchange
commission
sec
including
annual
report
form
filed
sec
april
statements
reflect
potential
impact
future
collaborations
acquisitions
mergers
dispositions
joint
ventures
investments
ascendis
may
enter
make
ascendis
assume
obligation
update
statements
except
required
law
ascendis
ascendis
pharma
ascendis
pharma
logo
company
logo
transcon
trademarks
owned
ascendis
pharma
group
september
ascendis
pharma
investor
contact
media
contact
patti
bank
ron
rogers
westwicke
partners
ascendis
pharma
rrs
ir
